Doctor Lisa Licitra

Doctor Lisa Licitra

Doctor Lisa Licitra (full registration at General Medical Council of Milan: 24943)

Birth: September 24th, 1959, in Milan

Nationality:Italian

Languages:Italian, English, German

Address:HospitalMedical Oncology - Dept. Of Medicine Istituto Nazionale Tumori

Via G. Venezian n. 1

20133 Milan - Italy

phone: +39 02 2390 2805

fax: +39 02 2390 2804

e-mail:

Home Via Sismondi 6

20133 Milano

phone: +39 02 70107660

Education, academical and professional degrees

1978High school degree (Scientific Lyceum-German School-Milan, Italy)

1984Degree in Medicine, cum laude(University of Milan, Italy)

1984Italian certificate of licensure to practice medicine

1987Postgraduate board in Clinical Oncology, cum laude (University of Parma, Italy)

Professional positions

April 1985 - March 1988 and July 1988 - April 1989

Recipient of a scholarship, Division of Medical Oncology,Istituto Nazionale Tumori, Milan, Italy

May 1989 - November 1991

Researcher, Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy

November 1991 - September 1992

Ad interim Assistant Physician, Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy

October 1992 - February 1994

Researcher, Division of Medical Oncology, Istituto Nazionale Tumori, Milan, italy

March 1994 - December 2001

Assistant Physician, Medical Oncology Unit “A”, Department of Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy.

January 2002 – April 2004

Assistant Physician, Medical Oncology Unit, Department of Head and Neck, Istituto Nazionale Tumori, Milan, Italy.

April 2002 to date

Chief of Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy.

Memberships

- Italian Association for Medical Oncology (AIOM)

- European Society for Medical Oncology (ESMO)

- European Organization for the Research and Treatment of Cancer (EORTC)

- American Society for Clinical Oncology (ASCO)

- Founding Member of AIOCC

- Member of American Association for Cancer Research (AACR)

Current scientific and editorial activities

  • Free-contract Professor at State University of Milan
  • Member of the Clinical Editorial Board of the Journal of Clinical Oncology
  • Editor of START - State-of-the-Art Oncology in Europe ( a project of Alleanza Contro il Cancro – Ministry of Health - Italy
  • Reviewer of the PDQ Summaries on head and neck cancers
  • Board Member of EORTC - European Organization for the Research and Treatment of Cancer (2009- 2012) Elected Chair of Head and Neck Cancer Cooperative Group of EORTC
  • Chair of Head and Neck Cancer Cooperative Group of EORTC (From June, 2012)
  • Co-founder and member of IGEO - Italian Group for the Evaluation of Outcomes in Oncology
  • Member of The Educational Committee of ESMO (European Society for Medical Oncology); Chair of the Head and Neck Faculty of ESMO
  • Co-founder and member, as medical oncologist, for the European Head and Neck Cancer Society
  • Member of the Clinical Editorial Board of Oral Oncology

Prize and Honorary

- European Society for Therapeutic Radiology and Oncology (ESTRO) – honorary Member

- Guido Venosta Prize by the President of the Republic of Italy

Current research fields of interest

-Head and Neck Neoplasms

-Evidence-based Medicine

-Clinical Methodology in Oncology and Quality of Life

Selected Publications

JOURNAL ARTICLES in English, reviewed by Medline

  • Guy Andry, Marc Hamoir, Laura D Locati, Lisa Licitra, Johannes A Langendijk, Management of salivary gland tumors Expert Rev. Anticancer Ther. 12(9), 1161–1168 (2012).
  • Paolo Bossi, Carlo Resteghini, Federica Perrone, Barbara Cortelazzi, Silvana Pilotti, Andrea Maurichi, Laura D. Locati, Lisa Licitra - Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma Journal of the American Academy of Dermatology Volume 67, Issue 5, November 2012, Pages e226–e228.
  • Paolo Bossi,Gabriela Kornek, Gaetano Lanzetta, Antonio Rozzi, Thorsten Fureder, Laura Locati, Lisa Licitra, Safety and feasibility of every-other-week maintenance cetuximab after first-line hemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer - Published online in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/hed.23170
  • Chan A.T.C., Grégoire V., Lefebvre J.-L., Licitra L.,. Hui E.P,. Leung S.F & Felip E.,Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology 23 (Supplement 7): vii83–vii85, 2012
  • Lisa Licitra & Laura D. Locati Multikinase inhibitors in thyroid cancer, Annals of Oncology 23 (Supplement 10): x328–x333, 2012 doi:10.1093/annonc/mds356
  • Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: Final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer. 2012 Mar 20. doi: 10.1002/cncr.27449. [Epub ahead of print]
  • Mehanna H, Olaleye O, Licitra L. Oropharyngeal cancer - is it time to change management according to human papilloma virus status? Curr Opin Otolaryngol Head Neck Surg. 2012 Apr;20(2):120-4.
  • Locati LD, Bossi P, Licitra L. How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma? J Clin Oncol. 2012 Feb 20;30(6):672; author reply 672-673. Epub 2012 Jan 17.
  • Bossi P, Locati LD, Licitra L. Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. J Clin Oncol. 2012 Feb 10;30(5):564-5; 565-567. Epub 2012 Jan 3.
  • Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L. Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol. 2011 Dec 21. [Epub ahead of print]
  • Liberato NL, Rognoni C, Rubrichi S, Quaglini S, Marchetti M, Gorlia T, Licitra L, Vermorken JB. Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. Ann Oncol. 2011 Nov 21. [Epub ahead of print]
  • Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L; RARECARE Working Group. Rare cancers of the head and neck area in Europe.Eur J Cancer. 2012 Apr;48(6):783-96. Epub 2011 Nov 1.
  • Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011 Nov;47(17):2493-511. Epub 2011 Oct 25.
  • Secondino S, Zecca M, Licitra L, Gurrado A, Schiavetto I, Bossi P, Locati L, Schiavo R, Basso S, Baldanti F, Maccario R, Locatelli F, Siena S, Pedrazzoli P, Comoli P. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol. 2012 Feb;23(2):435-41. Epub 2011 May 17.
  • Perrone F, Gloghini A, Cortelazzi B, Bossi P, Licitra L, Pilotti S. Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. Am J Surg Pathol. 2011 May;35(5):774-7; author reply 777-8.
  • Bossi P, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, Licitra L. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. Ann Oncol. 2011 Nov;22(11):2495-500. Epub 2011 Mar 11.
  • Federica Perrone;Annunziata Gloghini;Barbara Cortelazzi;Paolo Bossi;Lisa Licitra;Silvana Pilotti, M.D., MIAC ,Isolating p16 positive/HPV negative oropharyngeal cancer: an effort worth making, The American Journal of Surgical Pathology
  • Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB. . Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2010 Nov 3. [Epub ahead of print]
  • Bossi P, Granata R, Bergamini C, Mirabile A, Locati L, Licitra L. Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. Oral Oncol. 2010 Dec;46(12):888.
  • Chan AT, Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v187-9.
  • Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v184-6
  • Bernier J, Licitra L. Chemotherapy: Chemoradiation in head-and-neck cancer-are we any closer? Nat Rev Clin Oncol. 2010 May;7(5):247-9.
  • Psyrri A, Licitra L, Lacombe D, Schuuring E, Budach W, Ozsahin M, Knecht R, Vermorken JB, Langendijk JA. Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. Ann Oncol. 2010 Oct;21(10):1952-60. Epub 2010 Mar 19.
  • Licitra L, Laura D. Locati, Angela Greco, Roberta Granata, P. Bossi Multikinase inhibitors in thyroid cancer European Journal of Cancer - 19 February 2010 (10.1016/j.ejca.2010.01.010)
  • Bernier J, Licitra L.in head-and-neck cancer-are we any closer? Nat Rev Clin Oncol. 2010 May;7(5):247-9
  • Psyrri A, Burtness B, Harari PH, Vermorken JB, Licitra L, and Clarence T. Sasaki, Head and Neck Cancer, Journal of Oncology, vol. 2009
  • Perrone F, Licitra L, Pilotti S, Locati L, Bossi P, Orlandi E, Palazzi M, Olmi P. Oropharyngeal Squamous Cell Carcinoma Treated with Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. Int J Radiat Oncol Biol Phys 2009; 75 (4): 1053-1059
  • Ciccolallo L, Licitra L, Cantú G, Gatta G, the EUROCARE Working Group. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol 2009; 669–674.
  • Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2009; 27:1864-71.
  • Lefebvre JL, Ang KK; Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Head Neck. 2009; 31:429-41.
  • Palazzi M, Orlandi E, Bossi P, Pignoli E, Potepan P, Guzzo M, Franceschini M, Scaramellini G, Cantù G, Licitra L, Olmi P, Tomatis S. Further Improvement in Outcomes of Nasopharyngeal Carcinoma With Optimized Radiotherapy and Induction Plus Concomitant Chemotherapy: An Update of the Milan Experience. Int J Radiat Oncol Biol Phys. 2009; 74 (3) 774-780. [
  • Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009; 101:129-31.
  • van Herpen CM, Locati LD, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, Licitra L, Bernier J, Vermorken JB. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer 2008; 44: 2542-2545.
  • Licitra L, Zigon G, Gatta G, Sanchez M-J, Berrino F, EUROCARE Working Group. Human papillomavirus in HNSCC: a European Epidemiological perspective. Hematol Oncol Clin 2008; 22: 1143-1153.
  • Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol. 2008; 45 (7): 574-578
  • Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, Licitra L, Pilotti S. TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. Transl Oncol 2008; 1: 121-128.
  • Licitra L, Locati LD, Bossi P. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: New options. Ann Oncol 2008: 19 (Supplement 7): vii1-vii4.
  • Bossi P, Locati LD, Licitra L, Tagliabue E. Folate in head and neck squamous cell cancer chemoprevention: purposely left out? J Clin Oncol. 2008 Jul 10;26:3463. author reply 3463-4.
  • Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
  • Perrone F, Bossi P, Licitra L. TP53 mutations in head and neck cancer. N Engl J Med 2008; 358: 1194-1195.
  • Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantu’ G, Olmi P, M.D.* Effects of Treatment Intensification on Acute Local Toxicity During Radiotherapy For Head and Neck Cancer: a Prospective Observational Study Validating CTCAE v3.0 Scoring System. Int J Radiat Oncol Biol Phys 2008; 70: 330-337.
  • Bossi P, Locati LD, Licitra L. Biological agents in head and neck cancer. Exp Rev. Anticancer Ther 2007; 7: 1643-1650.
  • Perrone F, Luigi Mariani L, Pastore E, Orsenigo M, Suardi S, Marcomini B, Da Riva L, Licitra L, Carbone A, Pierotti MA, Pilotti S. Dp53 codon 72 polymorphisms in HPV-negative and HPV-positive squamous cell carcinomas of the oropharynx. Cancer 2007; 109: 2461-2465.
  • Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, Orlandi E, Olmi P, Tagliabue E, Ménard S, Licitra L. Previously irradiated areas spared from skin toxicity induced by cetuximab in 6 patients: implications for the administration of EGFR inhibitors in previously irradiated patients Ann Oncol 2007; 18. 601-602.
  • Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S. High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. J Clin Oncol 2006; 24: 5630-5636.
  • Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada GP, Losa M, Licitra L, Bossi P, Staurengo S, Oggionni M, Locati L, Cantù G, Squadrelli M, Carbone A, Pierotti MA, Pilotti S. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12: 6643-51.
  • Laurie SA, Licitra L. Special Series (Head and Neck): Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006; 24: 2373-2378.
  • Licitra L, Bossi P, Locati Laura D. A multidisciplinary approach to squamous cell carcinomas of the head and neck: what’s new? Curr Opin Oncol 2006; 18: 253-257.
  • Licitra L, Rossini C, Bossi P, Locati L. Advances in the changing patterns of aetiology of head and neck cancers. Curr Opin Otolaryngol Head Neck Surg 2006; 14: 95-99.
  • Licitra L, Bossi P, Locati L, Bergamini C. Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer? J Clin Oncol 2005; 23: 7757-8.
  • Bergamini C, Barisella M, Locati LD, Bossi P, Potepan P, Rinaldi G, Licitra L. Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas? Oral Oncol Extra 2005; 41: 219-221.
  • Locati L, Guzzo M, Bossi P, Brega Massone P, Conti B, Fumagalli E, Bareggi C, Cantù G, Licitra L. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol 2005 41: 890-4.
  • Cantù G, Solero CL, Miceli R, Mariani L, Mattavelli F, Squadrelli-Saraceno M, Bimbi G, Riccio S, Colombo S, Locati L, Olmi P, Licitra L. Which classification for ethmoid malignant tumors involving the anterior skull base? Head Neck 2005; 27: 224-231.
  • Locati L, Rinaldi G, Bossi P, Dagrada GP, Quattrone P, Cantù G, Licitra L. Herceptin plus chemotherapy in relapsed and/or metastatic salivary glands cancer. Oral Oncol 2005; 41: 97-98.
  • Licitra L, Suardi S, Bossi P, Locati L, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S. Prediction of TP53 status for primary PFL chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 2004; 22: 4901-4906
  • Licitra L, Locati LD, Bossi P. Head and neck cancer. Ann Oncol 2004; 15 (Suppl 4): iv267-iv273.
  • Licitra L, Locati LD, Bossi P, Cantù G. Head and neck tumors other than squamous cell carcinoma. Curr Opin Oncol 2004; 16: 236-241.
  • Licitra L, Bossi P, Locati L, Zunino F. Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible? J Clin Oncol 2004; 22: 377.
  • Licitra L, Vermmorken JB. Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann Oncol 2004; 15: 7-11.
  • Bimbi G, Saraceno MS, Riccio S, Gatta G., Licitra L, Cantu G. Adenocarcinoma of ethmoid sinnus: an occupational disease. Acta Otorhinolaryngol Ital 2004; 24: 199-203.
  • Palazzi M, Guzzo M, Bossi P, Tomatis S, Cerrotta A, Cantu G, Locati LD, Licitra L. Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapy. Tumori 2004; 90: 60-65.
  • Sanguineti G, Bossi P, Pou A, Licitra L. Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. Clin Oncol 2003; 15: 451-460.
  • Locati L, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L. A complete remission with androgen deprivation therapy in a recurrent androgen receptors expressing adecarcinoma of the parotid gland. Ann Oncol 2003; 14: 1327-1328.
  • Perrone F, Oggionni M, Birindelli S, Suardi S, Tabano S, Romano R, Moiraghi ML, Quattrone P, Cantù G, Pierotti MA, Licitra L, Pilotti S. TP53, p14arf, p16ink4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses (ITAC). Int J Cancer 2003; 105: 196-203.
  • Licitra L. Chemoradiation therapy in locally advanced nasopharyngeal cancer: which kind of cooperation? Ann Oncol 2003: 14: 508-509.
  • Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazzé S, Bruzzi P, Gatta G, Molinari R. Cancer of the nasopharynx. Crit Rev Oncol Hematol 2003; 45: 199-214.
  • Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R. Major and minor salivary glands tumours. Crit Rev Oncol Hematol 2003; 45: 215-225.
  • Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantù G. Primary chemotherapy in resectable oral cavity squamous cell carcinoma: a randomized controlled trial. J Clin Oncol 2003; 21: 327-333.
  • Licitra L, Locati L, Cavina R, Garassino I, Mattavelli F, Pizzi N, Quattrone P, Valagussa P, Gianni L, Bonadonna G, Solero CL, Cantù G. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol 2003; 14: 367-372.
  • Licitra L. Quality of Life instruments for head and neck cancer patients. An unsolved question. I supplementi di Tumori 2003; Vol. 2 No. 1: S48-S49.
  • Drago GP, Setti E, Licitra L, Liberati D. Forecasting the performance status of head and neck cancer patient treatment by an interval arithmetic pruned perceptron. Biomed Eng 2002; 49: 782-787.
  • Bareggi C, Palazzi M, Locati LD, Cerrotta A, Licitra L. Clozapine and full-dose concomitant chemo-radiation therapy in a schizophrenic patient with nasopharyngeal cancer. Tumori 2002; 88: 59-60.
  • Licitra L, Spinazzé S, Doci R, Evans TRJ, Tanum G, Ducreux M. Cancer of the anal region. Crit Rev Oncol Hematol 2002; 43: 77-92.
  • Licitra L, Spinazzé S, Rola F. Antiemetic therapy. Crit Rev Oncol Hematol 2002; 43: 93-101.
  • Locati LD, Quattrone P, Pizzi N, Fior A, Cantù G, Licitra L. Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosis: report of a case and review of the literature. Oral Oncol 2002; 38: 401-404.
  • Bernier J, Vermorken JB, Debruyne C, Andry G, Licitra L, Grandi C, Langendijk H, Lefebvre JL on behalf of the EORTC Head and Neck Cancer Group (HNCG). From chemoprevention and organ preservation programmes to post-operative management: major achievements and strategies of the EORTC Head and Neck Cancer Group. Eur J Cancer 2002; 38 Suppl 4: S75-81.
  • Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre JL. Cancer of the oropharynx. Crit Rev Oncol Hematol 2002; 41: 107-122.
  • Casali PG, Licitra L, Bruzzi P. QUOROM and the search for an updated ‘clinical method’ in the era of evidence-based medicine (Editorial). Ann Oncol 2000; 11: 923-925.
  • Costantini M, Mencaglia E, Giulio PD, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, Licitra L, Candis DD, Massidda B, Luzzani M, Campora E, Placido SD, Palmeri S, Angela PM, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L. Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology. Qual Life Res 2000; 9: 151-9.
  • Grandi C, Guzzo M, Cavina R, Gardani G, Tana S, Licitra L, Rossi N, Barbaccia C, Mingardo M, Fallahdar D, Bruno P, Molinari R. Treatment of cancer of the base of the tongue and glosso-epiglottic region: a multicenter Italian survey. GLOCC Group. Gruppo di Lavoro in Oncologia Cervico Cefalica. Tumori 2000; 86: 215-23.
  • Ruggeri B, Ballatori E, Casali P, Tamburini M, Licitra L, Mencaglia E, Roila F, Cortesi E, Massidda B, Costantini M (principal investigators, for the Italian Group for Evaluation of Outcomes in Oncology). Awareness of disease among Italian cancer patients: is there a need for further improvement in patient information? Ann Oncol 1999; 10: 1095-1100.
  • Cantù G, Solero CL, Mariani L, Mattavelli F, Pizzi N, Licitra L. A new classification for malignant tumors involving the anterior skull base. Arch Otolaryngol Head Neck Surg 1999; 125: 1252-7
  • Casali P, Licitra L, Tondini C, de Braud F, Bruzzi P, Costa A, Cavalli F. START: a European state-of-the-art on-line instrument for clinical oncologists. Ann Oncol 1999; 10: 769-73.
  • Roila F, Ballatori E, Mattei A, Cortesi E, Tamburini M, Casali P, Licitra L, Mencaglia E, Costantini M,Massidda B (principal investigators) for the Italian Group for Evaluation of Outcomes in Oncology (I.G.E.O.). Patient compliance with quality of life questionnaires. Tumori 1999; 85: 92-95.
  • Costa A, Licitra L, Veneroni S, Daidone MG, Grandi C, Cavina R, Molinari R, Silvestrini R. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer 1998; 79: 619-23.
  • Licitra L, Cavina R, Cerrotta A. A multidisciplinary approach in clinical oncology. Tumori 1998; 84: 279-80.
  • Casali P, Licitra L, Costantini M, Santoro A, Viterbori P, Bajetta E, Bruzzi P. Quality of life assessment and clinical decision-making. Ann Oncol 1997; 8: 1207-11.
  • Costantini M, Mencaglia E, Di Giulio P, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, Licitra L, Massidda B, Luzzani M, Campora E, De Placido S, Palmeri S, Palladino MA, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L. Evaluation of quality of life in oncology. Rationale and objectives of the first phase of the Quality of Life in Oncology project. Tumori 1997; 83(2 Suppl): S25-7.
  • Licitra L, Capri G, Fulfaro F, Grandi C, Tarenzi E, Cavina R, Gianni L. Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. Ann Oncol 1997; 8: 1157-8.
  • Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, Molinari R. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996; 7: 640-2.
  • Guzzo M, Grandi C, Licitra L, Podrecca S, Cascinelli N, Molinari R. Mucosal malignant melanoma of head and neck: forty-eight cases treated at Istituto Nazionale Tumori of Milan. Eur J Surg Oncol 1993; 19: 316-9.
  • Grandi C, Mingardo M, Guzzo M, Licitra L, Podrecca S, Molinari R. Salvage surgery of cervical recurrences after neck dissection or radiotherapy. Head Neck 1993; 15: 292-5.
  • Licitra L, Marchini S, Spinazze S, Rossi A, Rocca A, Grandi C, Molinari R.
    Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991; 68: 1874-7.

BOOKS in Italian

Top View